Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlodipine + valsartan + rosuvastatin
- Development stage
- Unknown
- Lead developer
- Kyungdong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amlodipine + valsartan + rosuvastatin is an oral fixed-dose combination of three small-molecule cardiovascular agents for patients with coexisting hypertension and hyperlipidemia. Amlodipine blocks L-type voltage-gated calcium channels to reduce vascular smooth-muscle tone and blood pressure; valsartan antagonizes the angiotensin II type 1 receptor to inhibit angiotensin II-mediated vasoconstriction and aldosterone signaling; and rosuvastatin competitively inhibits HMG-CoA reductase to lower hepatic cholesterol synthesis and circulating low-density lipoprotein cholesterol. The combination was clinically developed by HK inno.N as CJ-30060, including a completed Phase III trial in hypertensive patients with hyperlipidemia.
- Brand names
- KD5001KD-5001KD 5001CJ-30060CJ30060CJ 30060
- Other names
- amlodipine/valsartan/rosuvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on amlodipine + valsartan + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlodipine + valsartan + rosuvastatin.